The ZRT Laboratory Blog

The ZRT Blog is an extensive resource for patients and health care providers searching for health and hormone testing information. Here, you can read about ZRT’s cutting edge research, advances in testing, wellness advice, and health industry highlights.

Neurotransmitters, Mood & the Perception of Stress

Posted by Dr. Thomas Guilliams on Friday, 06 April

ThinkstockPhotos-668090816_lores

When we talk about “stress,” or allostatic load, in terms of the perception of an event, we must realize that these “events” must first be translated into neurochemical signals before they trigger the HPA axis.

Therefore, the sensitivity and outcome of translating these events (whether they are ongoing events, memories of past events, or stressful anticipation of unrealized events), is highly dependent upon signaling from other neurotransmitters. In fact, the signaling neurotransmitters that manage mood and affect often overlap with measures of HPA axis activation, and cannot be easily distinguished in some subjects. [1]

Read More

Looking Back: Popular Articles for Providers in 2017

Posted by ZRT Laboratory on Friday, 05 January

Female Doctor_lores.jpgAs we step into 2018, ready to deepen our understanding of the critical balance of hormones and neurotransmitters, as well as the role of elements in optimal health, we wanted to take a brief moment to reflect on the top stories of the past year.

Following is a round-up of 2017's most popular posts for practitioners.

Read More

Looking Back: Popular Articles for Patients in 2017

Posted by ZRT Laboratory on Friday, 05 January

ThinkstockPhotos-479706709_crop2.jpg2018 has begun, and with it comes new opportunity to understand the role of hormones, neurotransmitters and elements in our overall health. 

Let's take a quick trip down memory lane to reflect on the top stories of 2017 that captured your attention. 

Read More

Research Updates – Trials of HRT Started in Early Menopause

Posted by Margaret Groves on Friday, 15 September

ThinkstockPhotos-520098512.jpg

One of the primary objectives of the Women's Health Initiative was to see if postmenopausal hormone replacement therapy (HRT) improved long-term risk of coronary heart disease, among other chronic diseases.

However, the combined estrogen/progestin (Prempro) arm was halted in 2002, citing that the participants’ risk of cardiovascular disease outweighed any potential benefit of HRT in the prevention of colorectal cancer and bone fracture [1]. The conjugated equine estrogen (CEE)-only arm was also halted in 2004 citing no improvement in heart disease risk but an increased incidence of stroke, and no benefit in terms of fractures, although there was a reduced breast cancer risk [2].

Yet the WHI investigators published a report this week [3] after a cumulative follow-up of 18 years finding that there was no overall increase in all-cause, cardiovascular, or cancer mortality as a result of either Prempro or CEE-only treatment during their participation in the trial.

Read More